WallStreetZenWallStreetZen

NASDAQ: NTLA
Intellia Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

NTLA past revenue growth

How has NTLA's revenue growth performed historically?
Company
-30.4%
Industry
145.73%
Market
17.2%
NTLA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NTLA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NTLA's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NTLA earnings and revenue history

Current Revenue
$36.3M
Current Earnings
-$481.2M
Current Profit Margin
-1,326.5%

NTLA Return on Equity

Current Company
-43.9%
Current Industry
-63.5%
Current Market
188%
NTLA's Return on Equity (-43.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NTLA announces earnings.

NTLA Return on Assets

Current Company
-36.4%
Current Industry
2.9%
NTLA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NTLA Return on Capital Employed

Current Company
-40.58%
Current Industry
19.5%
NTLA's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NTLA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NTLA$36.28M-$472.22M-$481.19M+3.57%N/A
NAMS$15.32M-$192.24M-$192.32M-85.67%N/A
DYN$0.00-$233.48M-$235.94MN/AN/A
MRVI$288.95M$731.76M-$119.03M+18.47%N/A
GERN$237.00k-$174.78M-$184.13M-25.97%N/A
View Top Biotech Stocks

NTLA earnings dates

Next earnings date
May 2, 2024

Intellia Therapeutics Earnings & Revenue FAQ

What were NTLA's earnings last quarter?

On Invalid Date, Intellia Therapeutics (NASDAQ: NTLA) reported Q4 2023 earnings per share (EPS) of -$1.46, up 5.8% year over year. Total Intellia Therapeutics earnings for the quarter were -$132.16 million. In the same quarter last year, Intellia Therapeutics's earnings per share (EPS) was -$1.38.

If you're new to stock investing, here's how to buy Intellia Therapeutics stock.

What was NTLA's earnings growth in the past year?

As of Q2 2024, Intellia Therapeutics's earnings has grown year over year. Intellia Therapeutics's earnings in the past year totalled -$481.19 million.

What is NTLA's earnings date?

Intellia Therapeutics's earnings date is Invalid Date. Add NTLA to your watchlist to be reminded of NTLA's next earnings announcement.

What was NTLA's revenue last quarter?

On Invalid Date, Intellia Therapeutics (NASDAQ: NTLA) reported Q4 2023 revenue of -$1.92 million up 114.12% year over year. In the same quarter last year, Intellia Therapeutics's revenue was $13.57 million.

What was NTLA's revenue growth in the past year?

As of Q2 2024, Intellia Therapeutics's revenue has grown -30.4% year over year. This is 176.13 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Intellia Therapeutics's revenue in the past year totalled $36.28 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.